Primary Antibody Deficiency Panel, Sequencing and Deletion/Duplication

Last Literature Review: May 2022 Last Update:

Determine the genetic etiology of a primary antibody deficiency in affected individuals.

If a familial sequence variant has been previously identified, targeted sequencing for that variant may be appropriate; refer to the Laboratory Test Directory for additional information.

Primary antibody deficiency (PAD) syndromes are a group of rare genetic disorders affecting antibody (immunoglobulin) production. Three categories of primary antibody deficiencies include common variable immunodeficiency (CVID), agammaglobulinemia, and hyper-IgM syndrome. Symptoms may include unusual, opportunistic, or severe infections that typically affect multiple organs/organ systems. Other signs may include sepsis, failure to thrive, splenomegaly, autoimmune conditions, and neutropenia. Agammaglobulinemia and hyper-IgM syndrome usually occur within the first 2 years of life. CVID manifests at all ages, but most often in the second and third decade. Molecular testing is used to determine the genetic etiology of PAD in affected individuals.

Genetics

Genes

See Genes Tested table for genes included in the panel.

Incidence

Estimated at 1/10,000

Inheritance

X-linked, autosomal dominant, or autosomal recessive, depending on the causative gene

Test Interpretation

Methodology

This test is performed using the following sequence of steps:

  • Selected genomic regions, primarily coding exons and exon-intron boundaries, from the targeted genes are isolated from extracted genomic DNA using a probe-based hybrid capture enrichment workflow.
  • Enriched DNA is sequenced by massively parallel sequencing (MPS; also known as next generation sequencing [NGS]) followed by paired-end read alignment and variant calling using a custom bioinformatics pipeline. The pipeline includes an algorithm for the detection of large (single exon-level or larger) deletions and duplications.
  • Sanger sequencing is performed as necessary to fill in regions of low coverage and in certain situations, to confirm variant calls.
  • Large deletion/duplication calls made using MPS are confirmed by an orthogonal exon-level microarray when sample quality and technical conditions allow.

Clinical Sensitivity

  • Agammaglobulinemia, 90% 
  • Hyper-IgM syndrome, 75-80% 
  • CVID, 20% 

Analytic Sensitivity

For massively parallel sequencing:

Variant ClassAnalytic Sensitivity (PPA) Estimatea (%)
and 95% Credibility Region (%)
Analytic Specificity (NPA) (%)
SNVs>99 (96.9-99.4)>99.9
Deletions 1-10 bpb93.8 (84.3-98.2)>99.9
Insertions 1-10 bpb94.8 (86.8-98.5)>99.9
Exon-levelc deletions

97.8 (90.3-99.8) [2 exons or larger]

62.5 (38.3-82.6) [single exon]

>99.9
Exon-levelc duplications83.3 (56.4-96.4) [3 exons or larger]>99.9

aGenes included on this test are a subset of a larger methods-based validation from which the PPA values are derived. These values do not apply to testing performed by multiplex ligation-dependent probe amplification (MLPA).

bVariants greater than 10 bp may be detected, but the analytic sensitivity may be reduced.

cIn most cases, a single exon deletion or duplication is less than 450 bp and 3 exons span a genomic region larger than 700 bp.

bp, base pairs; NPA, negative percent agreement; PPA, positive percent agreement; SNVs, single nucleotide variants

Limitations

  • A negative result does not exclude a PAD syndrome.
  • Diagnostic errors can occur due to rare sequence variations.
  • Interpretation of this test result may be impacted if the individual has had an allogeneic stem cell transplantation.
  • The following will not be evaluated:
    • Variants outside the coding regions and intron-exon boundaries of the targeted genes
    • Regulatory region variants and deep intronic variants
    • Breakpoints of large deletions/duplications
    • Deletions/duplications in NFKBIA and TCF3
    • Translocations
    • The following exons are not sequenced due to technical limitations of the assay:
      • CXCR4 (NM_001348056, NM_001348059) exon(s) 2
      • DCLRE1C (NM_001350965) exon(s) 15
      • DCLRE1C (NM_001350966) exon(s) 13
      • DCLRE1C (NM_001350967) exon(s) 16
      • PRKCD (NM_001354676, NM_001354678) exon(s) 1
      • XIAP (NM_001167, NM_001204401, NM_001378590, NM_001378591, NM_001378592) exon(s) 4
  • The following may not be detected:
    • Deletions/duplications/insertions of any size by massively parallel sequencing
    • Large duplications less than 3 exons in size
    • Noncoding transcripts
    • Some variants due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions
    • Low-level somatic variants
    • Single exon deletions/duplications in the following exons: 
      • ADA (NM_000022, NM_001322051) 1; CXCR4 (NM_001348056) 2; CXCR4 (NM_001348059) 2; DCLRE1C (NM_001033855) 4-9; DCLRE1C (NM_001033857, NM_001289077) 6-10; DCLRE1C (NM_001033858, NM_001289079) 7-11; DCLRE1C (NM_001289076, NM_001289078) 3-7; DCLRE1C (NM_001350965) 4-9,15; DCLRE1C (NM_001350966) 3-7,13; DCLRE1C (NM_001350967) 6-10,16; DCLRE1C (NM_022487) 4-8; HELLS (NM_018063, NM_001289067, NM_001289068, NM_001289069, NM_001289070, NM_001289072) 7; HELLS (NM_001289071) 8; HELLS (NM_001289073) 6; IGLL (NM_152855) 2; IKZF1 (NM_001291846, NM_001291847) 4; MOGS (NM_001146158) 2; PRKCD (NM_001354676, NM_001354678) 1; XIAP (NM_001167, NM_001204401, NM_001378590, NM_001378592) 4; XIAP (NM_001378591) 5

Genes Tested

GeneMIM NumberDisorderInheritance
ADA608958

Adenosine deaminase deficiency, partial

Severe combined immunodeficiency due to ADA deficiency

AR
ADA2607575

Sneddon syndrome

Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome

AR
AICDA605257Immunodeficiency with hyper-IgM, type 2AR
ATM607585Ataxia-telangiectasiaAR
ATP6AP1300197Immunodeficiency 47XL
BLNK604515AgammaglobulinemiaAR
BTK300300

Agammaglobulinemia, X-linked 1

Isolated growth hormone deficiency, type III, with agammaglobulinemia

XL
CARD11607210Immunodeficiency 11AR

B-cell expansion with NFKB and T-cell energy

Immunodeficiency 11B with atopic dermatitis

AD
CD19107265CVID 3AR
CD27186711Lymphoproliferative syndrome 2AR
CD40109535Immunodeficiency with hyper-IgM, type 3AR
CD40LG300386Immunodeficiency, X-linked, with hyper-IgMXL
CD70602840Lymphoproliferative syndrome 3AR
CD79A112205Agammaglobulinemia 3AR
CD79B147245Agammaglobulinemia 6AR
CDCA7609937Immunodeficiency-centromeric instability-facial anomalies syndrome 3AR
CR2120650CVID 7AR
CTLA4123890Immune dysregulation with autoimmunity, immunodeficiency, and lymphoproliferationAD
CXCR4162643

Whim syndrome

Myelokathexis, isolated

AD
DCLRE1C605988

SCID, Athabascan type

Omenn syndrome

AR
DNMT3B602900Immunodeficiency-centromeric instability-facial anomalies syndrome 1AR
GATA2137295

Immunodeficiency 21

Emberger syndrome

AD
HELLS603946Immunodeficiency-centromeric instability-facial anomalies syndrome 4AR
ICOS604558CVID 1AR
IGHM147020Agammaglobulinemia 1AR
IGLL1146770Agammaglobulinemia 2AR
IKZF1603023CVID 13AD
IL21R605383IgE, elevated level ofAD
Immunodeficiency 56AR
KDM6A300128Kabuki syndrome 2XL
KMT2D602113Kabuki syndrome 1AD
LRBA606453CVID 8 with autoimmunityAR
MOGS601336Congenital disorder of glycosylation, type IIBAR
MS4A1112210CVID 5AR
NBN602667

Nijmegen breakage syndrome

Aplastic anemia

Leukemia, acute lymphoblastic

AR
NFKB1164011CVID 12 AD
NFKB2164012CVID 10AD
NFKBIA164008Ectodermal dysplasia and immunodeficiency 2AD
PIK3CD602839Immunodeficiency 14A, autosomal dominantAD
Immunodeficiency 14B, autosomal recessiveAR
PIK3CG601232Hyper-IgMAD
PIK3R1171833

Immunodeficiency 36

SHORT syndrome

AD
PLCG2600220

Autoinflammation, antibody deficiency, and immune dysregulation

Familial cold autoinflammatory syndrome 3

AD
PRKCD176977Autoimmune lymphoproliferative syndrome, type IIIAR
RAC2602049Immunodeficiency 73A and 73B with defective neutrophil chemotaxis and leukocytosisAD
RAG1179615

Combined cellular and humoral immune defects with granulomas

SCID, B-cell negative

Omenn syndrome

Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity

AR
RAG2179616

Combined cellular and humoral immune defects with granulomas

SCID, B-cell negative

Omenn syndrome

AR
RNF168612688RIDDLE syndromeAR
SH2D1A300490Lymphoproliferative syndrome, X-linked, 1XL
STAT3102582

Hyper-IgE recurrent infection syndrome

Autoimmune disease, multisystem, infantile-onset 1

AD
TCF3147141Agammaglobulinemia 8A, autosomal dominantAD
Agammaglobulinemia 8B, autosomal recessiveAR
TNFRSF13B604907

CVID 2

Immunoglobulin A deficiency

AR, AD
TRNT1612907

Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay

Retinitis pigmentosa and erythrocytic microcytosis

AR
TTC37614589Trichohepatoenteric syndrome 1AR
UNG191525Immunodeficiency with hyper-IgM syndrome, type 5AR
XIAP300079X-linked lymphoproliferative syndrome 2XL
ZBTB24614064Immunodeficiency-centromeric instability-facial anomalies syndrome 2AR
AD, autosomal dominant; AR, autosomal recessive; SCID, severe combined immunodeficiency; XL, X-linked

References